Fiche société
Dr. M.R. Meijerink
Traitements, essais et publications liés.
Traitements1programmes
Essais1liés
Publications0liées
SourceDBlocale
Traitements
1| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| Stereotactic ablative radiotherapy (SABR)Irreversible electroporation (IRE) is a promising new ablation technique to fight pancreatic cancer. The primary aim of the CROSSFIRE trial is to compare the efficacy (in terms of overall survival) of FOLFIRINOX and IRE (experimental arm) to the efficacy of FOLFIRINOX and stereotactic ablative radiotherapy (SABR) (control arm) in patients with locally advanced, non-resectable, non-metastasized, pancreatic cancer (LAPC). Secondary outcomes are progression free survival, safety/toxicity, immunomodulation, tumor marker Cancer Antigen (CA) 19.9, quality of life (QoL), and total direct and indirect costs for each treatment arm (cost-effectiveness analysis). | Cancer | Non applicable | Ralentissement de la progression | Netherlands | À vérifier |
Essais cliniques
1| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Irreversible Electroporation (IRE) | Cancer | Non applicable | NCT02791503 | CROSSFIRE Trial: Comparing the Efficacy of Irreversible Electroporation With Radiotherapy | COMPLETED |
Publications
0| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| Aucune publication. | ||||